1 2		
2 3 4	1	Characteristics of Canadians likely to try or increase cannabis use following legalization
5 6	2	for recreational purposes: A cross-sectional study
7 8	3	
9 10 11	4	Harman S. Sandhu, HBSc ¹ ; Laura N. Anderson, PhD ^{1,2} ; Jason W. Busse, PhD, DC ^{3,4}
12 13	5	
14 15	6	¹ Department of Health Research Methods, Evidence, and Impact, McMaster University,
16 17 18	7	Hamilton, ON, Canada.
19 20	8	² Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON,
21 22	9	Canada.
23 24 25	10	³ Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University,
26 27	11	Hamilton, ON, Canada.
28 29	12	⁴ Departent of Anesthesia, McMaster University, Hamilton, ON, Canada.
30 31 32	13	
33 34	14	Corresponding Author: Jason W. Busse, Department of Anesthesia, Michael G. DeGroote
35 36	15	School of Medicine, McMaster University, HSC-2V9, 1280 Main St. West, Hamilton, Canada,
37 38	16	L8S 4K1; email: bussejw@mcmaster.ca
39 40 41	17	
42 43	18	Funding: No funds were received for the preparation of this manuscript.
44 45	19	
46 47 48	20	Declaration of competing interests: The authors declare no competing interests.
49 50	21	
51 52	22	
53 54	23	
55 56 57		
57 58 59		
60		For Peer Review Only

ABSTRACT

Background: The Government of Canada legalized recreational use of cannabis in October 2018.

Methods: We used data from the 2018 National Cannabis Survey to investigate factors associated with intent to try or increase cannabis use post-legalization among Canadians using multivariable logistic regression. Respondents' data were weighted and bootstrapped. We report relative measures of association as adjusted odds ratios (aORs) and absolute measure of association as adjusted risk increases (ARIs).

Results: An estimated 18.5% (95%CI: 17.6–19.5) of the study population indicated that they

intended to try (15.7%) or increase (2.8%) cannabis use following legalization. Our weighted

analysis represented 27,808,081 Canadians 15 years of age or older (unweighted n = 17,089). In

our adjusted regression model, being more likely to try or increase cannabis use was associated

with younger age (15–24 years versus ≥65; aOR 3.8, 95%CI: 2.6–5.6; ARI 20.1%, 95%CI: 13.9–

26.2), cannabis use in the past three months versus not (aOR 3.3, 95%CI: 2.8–3.9; ARI 20.4%,

95%CI: 17.1–23.6), higher income (≥\$80,000 versus <\$40,000; aOR 1.5, 95%CI: 1.3–1.9; ARI

6.1%, 95%CI: 3.2–9.0), and poor or fair mental health compared to good or excellent mental

health (aOR 2.0, 95%CI: 1.6–2.6; ARI 11.5%, 95%CI: 6.7–16.2).

Interpretation: Nearly 1 in 5 respondents reported their intention to try or increase cannabis use post-legalization. Efforts to promote responsible use of cannabis should be a priority for clinicians, public health officials, and policymakers.

Keywords: Cannabis; Marijuana; Health behavior; Canada; Health policy; Public health

Total word count = 2234, max 2500.

Introduction

Cannabis refers to products of the dried leaves and flowers of the Cannabis sativa plant which is consumed for medical and recreational purposes.(1) Although recreational use of cannabis was illegal in Canada prior to October 2018, Canadians were the leading consumers of cannabis in the developed world.(2) According to the 2012 Canadian Community Health Survey (CCHS), 12.2% of Canadians aged 15 or older reported using cannabis in the past year.(3) Daily use was reported by 1.8% and was more common in males (2.4%) versus females (1.2%), and among those who were 18–24 years of age (4.9%).(3) A long-term trends study confirmed greater cannabis use among younger males and also showed that, from 2004 to 2015, past-year cannabis use increased among Canadians aged 25 and older.(4) Observational studies have shown that cannabis users are more likely to be involved in motor vehicle collisions, with a systematic review finding double the odds of being involved in a collision while under the influence of cannabis compared to unimpaired driving (OR 1.92, 95%CI: 1.35–2.73).(5) Cannabis use is also associated with anxiety, psychotic symptoms, chronic bronchitis, impaired respiratory function, and cannabis use disorder.(6-11) The lifetime risk of addiction among Canadians who used cannabis was estimated to be 6.8% in 2012 and an estimated 1.3% met criteria for cannabis abuse or dependence in the past year. (12) Moreover, the potency of illicit cannabis has increased from 4% in 1995, to 12% in 2014, in the United States

(US)(13), and higher potency has been shown to be associated with adverse health outcomes

such as greater emergency department visits involving drug use.(10,11,14,15)

In an effort to promote responsible use, deter criminal activity, and protect public health and safety, the federal government legalized the use of recreational cannabis on October 17th. 2018.(16) This is in addition to medical cannabis which has been legal in Canada since 2001.(17) There are concerns that recreational cannabis may increase use and subsequent harm.(18) The impact of legalization based on evidence from US States is mixed with some studies showing increased rates of use and other showing no change.(19–22) Moreover, a 2016 narrative review found inconsistent evidence for an association between policy change and increased uptake of cannabis among youth.(23) Monitoring cannabis use prevalence, patterns of use, and modes of use are crucial to determining the impact of policy change. (24) Statistics Canada, the national statistics agency, developed and implemented the 2018 National Cannabis Survey (NCS), a novel cross-sectional survey which aims to better understand the frequency of cannabis use and to monitor changes in attitudes and behavior as a result of legalization.(25) Our objectives were to: (1) determine the prevalence of Canadians (aged 15 years or older) likely to try or increase cannabis use after legalization for recreational purposes; and (2) explore characteristics associated with intent to try or increase use. Methods We followed standards set by the "Strengthening the Reporting of Observational Studies in Epidemiology" (STROBE) statement for reporting our study.(26)

1 Study design & respondents

This is a cross-sectional study involving analysis of the 2018 NCS master file.(25,27) The NCS was developed by Statistics Canada in consultation with the Public Health Agency of Canada, Department of Justice of Canada, and Public Safety Canada.(25) Cognitive testing of questionnaire content was conducted and validation of estimates was done through cross-tabulations of other data and consultation with Statistics Canada stakeholders. (25) The data used in this study were collected just prior to legalization of recreational cannabis, from February to September 2018 (waves 1–3).(25) Data from the three waves were independent of each other. and were combined and analyzed together. Participation in the NCS was voluntary and data were collected through an electronic questionnaire or computer-assisted telephone interview. (25) The study population consisted of non-institutionalized Canadians, aged 15 years or older, residing in Canada's 10 provinces and three territory capital cities.(25) The sampling method was two-stage (dwelling and person) stratified by province or territory, and a simple random sample of dwellings which aimed to represent the Canadian population. (25) The NCS master file was accessed through the McMaster University Statistics Canada Research Data Centre.(28) Measures

Our primary outcome measure was derived from an NCS question that asked when cannabis consumption becomes legal for recreational purposes, would respondents be more likely to try cannabis or increase their consumption?(27) Response options included: "Yes", "Maybe", or "No". We also summarized whether respondents would be more likely to try different types of cannabis products or acquire cannabis from another source after legalization. Information on gender, age, cannabis use in the past three months, education and income level, main activity

during the previous week, and self–reported mental health were also collected and analyzed for association with intention to try or increase cannabis use. Categories for age, education level, income level, main activity, and self–reported mental health were collapsed to ensure adequate cell size and simplify analysis and subsequent interpretation. The full questionnaire is available through Statistics Canada.(27)

7 Statistical analysis

Descriptive statistics were used to summarize the data. We constructed univariable and multivariable logistic regression models to explore factors associated with the intent to try or increase cannabis use following legalization (those who responded "Yes or Maybe" compared to those who answered "No"). Of the individuals that endorsed the intent to try or increase cannabis use after legalization, we considered those who had not used cannabis in the past three months to be new users. Our independent variables were: (1) gender; (2) age; (3) cannabis use in past three months; (4) education level; (5) income level; (6) main activity during the previous week; and (7) self-reported mental health. We also adjusted our multivariable regression model for survey wave and province or territory of residence. Results are presented as aORs along with 95% confidence intervals (95%CIs). All analyses were two-tailed and statistical significance was defined as p < 0.05.

Prior to analysis, we reviewed unweighted frequencies of the independent variables to ensure
adequate cell sizes (at least 10 events per variable).(29) Bootstrap weights provided by Statistics
Canada were applied to convert unweighted frequencies to represent the Canadian population
and adjust for biases in the survey sampling design.(30) Missing data were excluded from our

regression analysis using listwise deletion. For all statistically significant associations in our adjusted model, we calculated adjusted risk increases (ARI) by subtracting the risk of the outcome in the referent group (e.g. age ≥ 65) from the risk in the comparator group (e.g. age 15-24), while holding all other variables constant.(31) The likelihood ratio test was performed to determine if the multivariable logistic regression model fit significantly better than a model with no predictors and the Wald test determined significance of individual predictors in the model. A Hosmer-Lemeshow test was performed to assess goodness-of-fit of our adjusted model.(32) All analyses were performed using Stata/SE 15 software.(33) Ethics consideration As per the Tri–Council Policy Statement: Ethical Conduct for Research Involving Humans Article 2.2 (a), research is exempt from research ethics board review if it relies exclusively on publicly available information that is legally accessible to the public and appropriately protected by law.(34) Our results were reviewed by a Statistics Canada Research Data Centre Analyst prior to release to ensure confidentiality of survey respondents. **Results** Of 39,000 households selected for recruitment of NCS waves 1–3, 17,089 respondents had provided complete data and were included in our multivariable logistic regression analysis (survey completion rate = 43.8%).(25) There was an equal distribution of males and females, most were employed (59.2%), the majority (93.8%) reported good to excellent mental health, and 15.2% reported use of cannabis in the past three months (Table 1). The "please specify" category of gender was removed from analysis and not reported due to very low response (n <

10). Overall, 18.5% (95%CI: 17.6–19.5) of individuals were likely to try or increase their recreational use of cannabis following legalization with an estimated 15.7% being new users. Almost a quarter of respondents (22.6%, 95%CI: 21.7–23.6) were likely to try different types of cannabis products and 16.7% (95%CI: 15.8–17.6) were likely to acquire cannabis from a new source (see Figure 1).
In our adjusted model, younger age (15–24 years OR 3.8, 95%CI: 2.6–5.6; ARI 20.1%, 95%CI:

8 13.9–26.2), cannabis use in past three months (OR 3.3, 95%CI: 2.8–3.9; ARI 20.4%, 95%CI:

9 17.1–23.6), higher income (≥\$80,000 OR 1.5, 95%CI: 1.3–1.9; ARI 6.1%, 95%CI: 3.2–9.0), and

10 poor or fair mental health (OR: 2.0, 95%CI: 1.6–2.6; ARI 11.5%, 95%CI: 6.7–16.2) were

11 associated with a greater likelihood of trying or increasing cannabis use following legalization

12 compared to referent categories (Table 2). The Hosmer-Lemeshow (p = 0.46) and likelihood

17.3

13 ratio (p < 0.05) tests suggested good fit of our adjusted model.

15 Interpretation

The NCS data collected prior to legalization suggests that nearly 1 in 5 Canadians intend on trying or increasing cannabis use following legalization for recreational purposes with a majority being new users. Those who are younger, used cannabis in the past three months, report higher income and poorer mental health were significantly more likely to try or increase cannabis use following legalization. Furthermore, we found that almost 1 in 4 Canadians were likely to try consuming different types of cannabis products, which will become legally available in October 2019.(35) A 2017 survey of 1,087 Canadians found that up to 46% are willing to try cannabis-infused food products.(36) In addition, a 2018 Deloitte survey found that 58% Canadian

cannabis users prefer edible products.(37) We also found that 1 in 6 respondents intended to obtain cannabis from alternate sources after legalization and the Deloitte survey found that Canadian cannabis users will shift up to 63% of their purchases towards legal channels.(37) Further complementing our findings, a 2014 survey of 3,532 US adults aged 18 to 34 found that 13.5% reported they would use cannabis more frequently if it were legalized.(38) This may be cause for concern as younger individuals are at a higher risk of experiencing harms associated with cannabis use: (7,10,11,39–41) however, intent may or may not translate into action. Consistent with our findings, the 2014 US study also found that cannabis non-users experiencing anxiety were more likely to endorse interest in trying cannabis if it were legal.(38) Although some studies have reported an association between cannabis use and mental illness (e.g. early onset psychosis among those who are predisposed, depression, anxiety, substance use disorder), management of psychiatric disorders is also one of the top cited reasons for cannabis use.(41–45) The association may therefore be bi-directional. The Canadian Psychiatric Association released a position statement in 2018 highlighting concerns over the impact of increased access to cannabis and mental health, particularly for youth.(46) Healthcare incidences involving cannabis increased following legalization in Colorado(47), and cannabis-related hospitalizations have been shown to be associated with higher rates of mental illness.(48,49)

There is also evidence to suggest that the general public may underestimate harms associated
with cannabis. A 2017 national survey of 16,280 US adults found 22.4% believe cannabis is not
addictive and 9% believe there are no risks associated with cannabis use.(50) A 2013 qualitative
study of 76 Canadian youth (aged 14–19 years) found that many were unaware of the potential

harms associated with cannabis use, highlighting a potential area for further education.(51) Continued national-level monitoring of changing attitudes and behaviours regarding cannabis use through surveys like the NCS will help assess the public health impact of cannabis legalization.(4,21,52)

Limitations

Self-reported use of cannabis and intention to try or increase use may be subject to measurement error and bias. It is possible that prevalence of cannabis use may have been underreported, although a number of studies have found self-reported cannabis use to be as reliable as other self-reported behaviors. (7,53,54) There is a potential for non-response bias due to sampling design and the completion rate, however bootstrap weighting by Statistics Canada attempts to addresses this by adjusting the representation of the data to be closer to the intended sample. Furthermore, the NCS did not collect information on institutionalized persons and our findings may not be generalizable to this population. Finally, the NCS data used for our study only measured intentions to use cannabis, not actual changes in behaviour, and only associations are reported.

Conclusion

Almost 1 in 5 Canadians intend to try or increase cannabis use following legalization for recreational purposes; particularly those who are younger, have used cannabis in the past three months, have higher income, and self-report their mental health as poor or fair. Clinicians, public health officials, and policymakers should pay special attention to these higher–risk populations to ensure informed decision-making and responsible use. Continued monitoring

through national-level surveys, such as the NCS, will be crucial in establishing rates and patterns of cannabis use among Canadians after recreational use becomes legal.

Acknowledgements: We would like to thank Dr. Li Wang, Dr. Peter Kitchen, and Dr. Mustafa

Ornek (McMaster University Statistics Canada Research Data Centre) and Dr. Behnam Sadeghi (Department of Health Research Methods, Evidence, and Impact, McMaster University) for statistical support. We also thank Dr. Emmanuel Guindon (Department of Health Research Methods, Evidence, and Impact, McMaster University) for review of our manuscript.

Data access: The 2018 National Cannabis Survey master file can be accessed through a

Statistics Canada Research Data Centre. The analysis code can be accessed by contacting the

corresponding author.

2 3 4	1	Refe	References			
5 6	2	1.	Russo E. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic			
 Potential. Routledge; 2003. 						
9 10 11	4	2.	United Nations Office on Drugs and Crime. Recent Statistics and Trend Analysis of Illie			
12 13	5 IFIG Markets = Lannanis Liverview Linternet LVienna Alistria: $/11/L$ Availanie i					
14 15	6		https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf			
16 17 18	7	3.	Rotermann M, Langlois K. Prevalence and correlates of marijuana use in Canada, 2012.			
19 20	8		Heal Rep. 2015;26(4):10–5.			
21 22	9	4.	Rotermann M, Macdonald R. Analysis of trends in the prevalence of cannabis use in			
23 24 25	10		Canada, 1985 to 2015 [Internet]. Statistics Canada; 2018 [cited 2019 Jan 9]. Available			
25 26 27	11		from: http://www.statcan.gc.ca/pub/82-003-x/2018002/article/54908-eng.htm			
28 29	12	5.	Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle			
30 31	13		collision risk: Systematic review of observational studies and meta-analysis. BMJ			
32 33 34	14		[Internet]. 2012 Feb 9 [cited 2018 Dec 7];344(7846):e536. Available from:			
35 36	15		http://www.ncbi.nlm.nih.gov/pubmed/22323502			
37 38	16	6.	Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet.			
39 40 41	17		2009;374(9698):1383–91.			
42 43	18	7.	Hall W, Pacula RL. Cannabis use and dependence : public health and public policy.			
44 45	19		Melbourne: Cambridge University Press; 2003. 298 p.			
46 47 48	20	8.	Budney AJ, Hughes JR. The cannabis withdrawal syndrome [Internet]. Vol. 19, Current			
48 49 50	21		Opinion in Psychiatry. 2006 [cited 2018 Mar 15]. p. 233-8. Available from:			
51 52	22		https://insights.ovid.com/crossref?an=00001504-200605000-00002			
53 54	23	9.	Roffman R, Stephens R. Cannabis dependence: its nature, consequences and treatment.			
55 56 57						
58 59			12			
			For Poor Poview Only			

```
Page 19 of 28
```

1 2					
2 3 4	1		Camebridge, United Kingdom: Cambridge University Press; 2006.		
5 6	2	10.	Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana		
7 8	3		Use. N Engl J Med [Internet]. 2014;370(23):2219–27. Available from:		
9 10 11	4		http://www.nejm.org/doi/10.1056/NEJMra1402309		
12 13	5	11.	Hall W. What has research over the past two decades revealed about the adverse health		
14 15	6		effects of recreational cannabis use? Addiction. 2015;110(1):19-35.		
16 17 18	7	12. Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada. Stat Canada C			
19 20	8		[Internet]. 82–624–X. Available from: https://www150.statcan.gc.ca/n1/pub/82-624-		
21 22	9		x/2013001/article/11855-eng.htm		
23 24 25	10	13.	ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis		
25 26 27	11		potency over the last 2 decades (1995-2014): Analysis of current data in the United States.		
28 29	Biol Development 2016 April Lotted 2018 Oct 11.70(7).(12. 0. Available for				
30 31 32	13		http://www.ncbi.nlm.nih.gov/pubmed/26903403		
32 33 34	14	14.	Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially		
35 36	15		of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.		
37 38	16		Schizophr Bull [Internet]. 2014 Nov 1 [cited 2018 Mar 15];40(6):1509–17. Available		
39 40 41	17		from: https://academic.oup.com/schizophreniabulletin/article-		
42 43	18		lookup/doi/10.1093/schbul/sbt181		
44 45	19	15.	Substance Abuse and Mental Health Services Administration. Drug Abuse Warning		
46 47 48	20		Network 2011: National Estimated of Drug-related Emergency Department Visits.		
49 50	21		Rockville, MD. HHS Publication No. (SMA) 13-4760, DAWN Series D-39; 2013.		
51 52	22	16.	Parliament of Canada. Government Bill (House of Commons) C-45 (42-1) - Royal Assent		
53 54	23		- Cannabis Act [Internet]. [cited 2019 Jan 9]. Available from:		
55 56 57					
58 59			13		
60			For Peer Review Only		

2 3 4	1		http://www.parl.ca/DocumentViewer/en/42-1/bill/C-45/royal-assent
5 6	2	17.	Fischer B, Kuganesan S, Room R. Medical marijuana programs: Implications for cannabis
7 8 9	3		control policy - Observations from Canada. Int J Drug Policy [Internet]. 2015;26(1):15-9.
9 10 11	4		Available from: http://dx.doi.org/10.1016/j.drugpo.2014.09.007
12 13	5	18.	Kelsall D. Watching Canada's experiment with legal cannabis. CMAJ [Internet]. 2018 Oct
14 15	6		15 [cited 2018 Dec 13];190(41):E1218. Available from:
16 17 18	7		http://www.ncbi.nlm.nih.gov/pubmed/30322984
19 20	8	19.	Cerdá M, Wall M, Feng T, Al E. Association of state recreational marijuana laws with
21 22	9		adolescent marijuana use. JAMA Pediatr [Internet]. 2016 [cited 2018 Sep 2]; Available
23 24 25	10		from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2593707
26 27	11	20.	Kerr DCR, Bae H, Koval AL. Oregon recreational marijuana legalization: Changes in
28 29	12		undergraduates' marijuana use rates from 2008 to 2016. Psychol Addict Behav [Internet].
30 31 32	13		2018 [cited 2018 Sep 2]; Available from:
32 33 34	14		https://www.researchgate.net/profile/David_Kerr2/publication/325344990_Oregon_recrea
35 36	15		tional_marijuana_legalization_Changes_in_undergraduates'_marijuana_use_rates_from_2
37 38	16		008-2016/links/5b06ebdfa6fdcc8c252432e2/Oregon-recreational-marijuana-legalization-
39 40 41	17		Chang
42 43	18	21.	Ghosh TS, Vigil DI, Maffey A, Tolliver R, Van Dyke M, Kattari L, et al. Lessons learned
44 45	19		after three years of legalized, recreational marijuana: The Colorado experience. Prev Med
46 47 48	20		(Baltim) [Internet]. 2017 [cited 2018 Sep 2];104:4-6. Available from:
49 50	21		https://www.sciencedirect.com/science/article/pii/S0091743517300762
51 52	22	22.	Estoup AC, Moise-Campbell C, Varma M, Stewart DG. The Impact of Marijuana
53 54 55	23		Legalization on Adolescent Use, Consequences, and Perceived Risk. Subst Use Misuse
55 56 57			
58 59			14
60			For Peer Review Only

1 2			
2 3 4	1		[Internet]. 2016 Dec 5 [cited 2018 Sep 2];51(14):1881-7. Available from:
5 6	2		https://www.tandfonline.com/doi/full/10.1080/10826084.2016.1200623
7 8	3	23.	Dirisu O, Shickle D, Elsey H. Influence of legal status on the uptake of cannabis in young
9 10 11	4		people [Internet]. Vol. 29, Current Opinion in Psychiatry. 2016 [cited 2018 Dec 16]. p.
12 13	5		231–5. Available from:
14 15	6		http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00001504-
16 17 18	7		201607000-00002
19 20	8	24.	Fischer B, Russell C, Rehm J, Leece P. Assessing the public health impact of cannabis
21 22	9		legalization in Canada: core outcome indicators towards an 'index' for monitoring and
23 24 25	10		evaluation. J Public Health (Bangkok) [Internet]. 2018 [cited 2018 Dec 1]; Available
26 27	11		from: https://academic.oup.com/jpubhealth/advance-
28 29	12		article/doi/10.1093/pubmed/fdy090/5025670
30 31 32	13	25.	Statistics Canada. National Cannabis Survey (NCS) [Internet]. 2018 [cited 2019 Jan 9].
33 34	14		Available from:
35 36	15		http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5262
37 38 39	16	26.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
40 41	17		Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
42 43	18		Statement: Guidelines for Reporting Observational Studies. PLoS Med [Internet]. 2007
44 45	19		Oct 16 [cited 2018 Dec 11];4(10):e296. Available from:
46 47 48	20		https://dx.plos.org/10.1371/journal.pmed.0040296
49 50	21	27.	Statistics Canada. National Cannabis Survey Questionnaire [Internet]. 2018 [cited 2019
51 52	22		Jan 9]. Available from:
53 54 55	23		http://www23.statcan.gc.ca/imdb/p3Instr.pl?Function=assembleInstr⟨=en&Item_Id=
56 57			
58 59			15
60			For Peer Review Only


2 3 4	1		1173861					
5 6	2	28.	Statistics Canada. The Research Data Centres (RDC) Program [Internet]. [cited 2019 Jan					
7 8 9	3]. Available from: https://www.statcan.gc.ca/eng/rdc/index					
9 10 11	4	29.	Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the					
12 13	5	number of events per variable in logistic regression analysis. J Clin Epidemiol [Internet].						
14 15 16	6		1996 Dec;49(12):1373-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8970487					
17 18	7	30.	Gagne C, Roberts G, Keown L-A. Weighted estimation and bootstrap variance estimation					
19 20	8		for analyzing survey data: How to implement in selected software. Ottawa, ON; 2014.					
21 22 22	9	31.	Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences					
23 24 25	10		in Stata. Stata J [Internet]. 2013;13(3):492–509. Available from:					
26 27	11		https://pdfs.semanticscholar.org/28cb/e7852bb3d11c5e9518c0a7a06ce022a89ccb.pdf					
28 29	12	32.	Hosmer DW, Lemeshow S. Goodness of fit tests for the multiple logistic regression					
30 31 32	13		model. Commun Stat - Theory Methods [Internet]. 1980 [cited 2018 Dec 7];9(10):1043-					
33 34	14		69. Available from: http://www.tandfonline.com/doi/abs/10.1080/03610928008827941					
35 36	15	33.	StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC;					
37 38 39	16		2017.					
40 41	17	34.	Canadian Institutes of Health Research, Natural Sciences and Engineering Research					
42 43	18		Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-					
44 45	19		Council Policy Statement: Ethical conduct for research involving humans. Medical					
46 47 48	20		Research Council of Canada. 2014. 1-10 p.					
49 50	21	35.	Hansen L. Cannabis edibles, drinks will mark "2nd wave" of legalization CBC News.					
51 52	22		2018 Nov 12; Available from: https://www.cbc.ca/news/canada/ottawa/cannabis-					
53 54 55	23		legalization-second-wave-edibles-1.4901297					
56 57								
58 59			16					
60			For Peer Review Only					

1			
2 3 4	1	36.	Charlebois S, Somogyi S. Marijuana-infused food and Canadian consumers' willingness
5 6	2		to consider recreational marijuana as a food ingredient [Internet]. 2017 [cited 2019 Jan 9].
7 8	3		Available from:
9 10 11	4		https://cdn.dal.ca/content/dam/dalhousie/pdf/management/News/Preliminary results
12 13	5		cannibis-infused foods EN.pdf
14 15	6	37.	Deloitte. A society in transition, an industry ready to bloom [Internet]. 2018 [cited 2019
16 17 18	7		Jan 9]. Available from:
19 20	8		https://www2.deloitte.com/content/dam/Deloitte/ca/Documents/consulting/ca-cannabis-
21 22	9		2018-report-en.PDF
23 24 25	10	38.	Cohn AM, Johnson AL, Rose SW, Rath JM, Villanti AC. Support for Marijuana
23 26 27	11		Legalization and Predictors of Intentions to Use Marijuana More Often in Response to
28 29	12		Legalization Among U.S. Young Adults. Subst Use Misuse [Internet]. 2017 Jan 28 [cited
30 31 32	13		2018 Sep 16];52(2):203–13. Available from:
32 33 34	14		https://www.tandfonline.com/doi/full/10.1080/10826084.2016.1223688
35 36	15	39.	Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between
37 38	16		marijuana smoking and lung cancer: A systematic review [Internet]. Vol. 166, Archives of
39 40 41	17		Internal Medicine. American Medical Association; 2006 [cited 2018 Mar 15]. p. 1359-67.
42 43	18		Available from:
44 45	19		http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.166.13.1359
46 47 48	20	40.	Kandel DB. Examining the Gateway Hypothesis: Stages and Pathways of Drug
49 50	21		Involvement. In: Stages and Pathways of Drug Involvement [Internet]. 2002 [cited 2018
51 52	22		Mar 15]. p. 3–16. Available from:
53 54 55	23		https://books.google.ca/books?hl=en&lr=&id=N5HAU639wnMC&oi=fnd&pg=PR9&dq=
56 57			
58 59			17
60			For Peer Review Only

3 4	1		DB+K and el+Stages+ and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of the stages + and + pathways+ of + drug+ involvement: + examining + the + gateway+ hy low of + drug+ involvement: + examining + the + gateway+ hy low of + drug+ involvement: + examining + the + gateway+ hy low of + drug+ involvement: + examining + the + gateway+ hy low of + drug+ involvement: + examining + drug+ involvement + examining + dr
5 6	2		pothesis,+Cambridge+University+Press,+New+York+(2002)&ots=KDpqGJ9D6W&sig=
7 8	3		WjZTFORoilbrpPTHqnaRjGF8D6c
9 10 11 12 13	4	41.	Memedovich KA, Dowsett LE, Spackman E, Noseworthy T, Clement F. The adverse
	5		health effects and harms related to marijuana use: an overview review. C Open [Internet].
14 15	6		2018 [cited 2018 Sep 16];6(3):E339-46. Available from:
16 17 18	7		http://cmajopen.ca/content/6/3/E339.full
19 20	8	42.	Walsh Z, Gonzales R, Crosby K, Carroll C. Medical cannabis and mental health: a
21 22	9		systematic review. Clin Psychol Rev [Internet]. 2017;51:15–29. Available from:
23 24 25	10		https://www.sciencedirect.com/science/article/pii/S0272735816300939
25 26 27	11	43.	Ogbome AC, Smart RG, Weber T, Birchmore-Timney C. Who is using cannabis as a
28 29 30 31 32 33 34 35 36	12		medicine and why: An exploratory study. J Psychoactive Drugs [Internet]. 2000 Dec 6
	13		[cited 2018 Sep 2];32(4):435-43. Available from:
	14		http://www.tandfonline.com/doi/abs/10.1080/02791072.2000.10400245
	15	44.	Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for
37 38	16		therapeutic purposes: Patient characteristics, access, and reasons for use. Int J Drug Policy
39 40 41	17		[Internet]. 2013 Nov 1 [cited 2018 Mar 31];24(6):511-6. Available from:
42 43	18		http://www.ijdp.org/article/S0955-3959(13)00135-7/fulltext
44 45	19	45.	Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis
46 47	20		for chronic neuropathic pain: a randomized controlled trial. CMAJ [Internet]. 2010 [cited
48 49 50	21		2018 Sep 2];182(14):E694-701. Available from:
51 52	22		http://www.cmaj.ca/content/182/14/E694.short?casa_token=3FbMpiUjELsAAAAA:zMP
53 54	23		oogYvy9GswcTRkZKcOcaoULWNwu1DAmrrmFaAPfDi3MSWjBx_Zsy2hqvsGF3udX
55 56 57			
58 59			18
60			For Peer Review Only

2						
3 4	1		NDq4c0sr_k			
5 6	2	46.	Tibbo P, Cracker CE, Lam RW, Meyer J, Sareen J, Aitchison KJ. Implications of			
 7 8 3 Cannabis Legalization on Youth and Young Adults [Internet]. Vol. 63, Cana 9 						
10 11	4		of Psychiatry. 2018 [cited 2018 Dec 16]. p. 65-71. Available from:			
12 13	5		http://journals.sagepub.com/doi/10.1177/0706743718759031			
14 15	6	47.	Vigil DI, Van Dyke M, Hall KE, Contreras AE, Ghosh TS, Wolk L. Marijuana Use and			
16 17 18	7		Related Health Care Encounters in Colorado Before and After Retail Legalization. Int J			
19 20	8		Ment Health Addict [Internet]. 2018 Aug 18 [cited 2018 Dec 16];16(4):806–12. Available			
21 22	9		from: http://link.springer.com/10.1007/s11469-018-9901-0			
23 24 25	10	48.	Wang GS, Hall K, Vigil D, Banerji S, Monte A, VanDyke M. Marijuana and acute health			
26 27	11		care contacts in Colorado. Prev Med (Baltim) [Internet]. 2017 Nov 1 [cited 2018 Dec			
28 29	12		16];104:24–30. Available from: https://www-sciencedirect-			
30 31 32	13		com.libaccess.lib.mcmaster.ca/science/article/pii/S0091743517301202			
33 34	14	49.	Wang GS, Davies SD, Halmo LS, Sass A, Mistry RD. Impact of Marijuana Legalization			
35 36	15		in Colorado on Adolescent Emergency and Urgent Care Visits. J Adolesc Heal [Internet].			
37 38	16		2018 Aug 1 [cited 2018 Dec 16];63(2):239-41. Available from: https://www-			
39 40 41	17		sciencedirect-com.libaccess.lib.mcmaster.ca/science/article/pii/S1054139X18300041			
42 43	18	50.	Keyhani S, Steigerwald S, Ishida J, Vali M, Cerdá M, Hasin D, et al. Risks and benefits of			
44 45	19		marijuana use a national survey of U.S. Adults. Ann Intern Med [Internet]. 2018 Sep 4			
46 47 48	20		[cited 2018 Dec 7];169(5):282–90. Available from:			
49 50	21		http://www.ncbi.nlm.nih.gov/pubmed/30039154			
51 52	22	51.	Porath-Waller A, Brown J, Clark H. What Canadian youth think about cannabis [Internet].			
53 54 55	23		Canadian Centre on Substance Abuse. 2013 [cited 2019 Jan 9]. p. 1–57. Available from:			
56 57						
58 59			19			
60			For Peer Review Only			

1									
2 3 4	1		http://www.ccdus.ca/Resource Library/CCSA-What-Canadian-Youth-Think-about-						
5 6	2		Cannabis-2013-en.pdf						
7 8 9	3	52.	Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States,						
) 10 11	4		2015–2016. Drug Alcohol Depend [Internet]. 2018 Oct 1 [cited 2018 Sep 30];191:374–81.						
12 13	5		Available from:						
14 15 16	6		https://www.sciencedirect.com/science/article/pii/S0376871618304538?via%3Dihub						
17 18	7	53.	O'malley PM, Bachman JG, Johnston LD. Reliability and Consistency in Self-Reports of						
19 20 21	8		Drug Use. Int J Addict [Internet]. 1983 Jan 3 [cited 2018 Mar 14];18(6):805–24. Available						
21 22 23	9		from: http://www.tandfonline.com/doi/full/10.3109/10826088309033049						
24 25	10	54.	Harrison ER, Haaga J, Richards T. Self-Reported Drug Use Data: What Do They Reveal?						
26 27 28	11		Am J Drug Alcohol Abuse [Internet]. 1993 Jan 7 [cited 2018 Mar 14];19(4):423–41.						
28 29 30	12		Available from: http://www.tandfonline.com/doi/full/10.3109/00952999309001632						
31 32	13								
33 34 35	14								
36 37	15								
38	16								
39	17								
40 41	18								
42	19								
43	20								
44	21								
45	22 23								
46 47	25 24								
48	24 25								
49	26								
50	27								
51	28								
52 53	29								
55	30								
55	31								
56									
57 58			20						
58 59			20						
60			For Peer Review Only						



Variable	Level	Percent (95%CI)
Gender	Female	50.3% (50.0-50.6)
	Male	49.7% (49.4–50.0)
Age (Years)	65 or older	18.5% (18.2–18.7)
	45–64	32.6% (32.3-32.9)
	35–44	16.6% (16.4–16.8)
	25–34	19.5% (18.7–20.4)
	15–24	12.9% (12.0–13.7)
Cannabis use in	No	84.8% (84.0-85.7)
past 3 months	Yes	15.2% (14.3–16.0)
Education Level	Bachelor's or higher	32.7% (31.7–33.8)
	College or Diploma	33.7% (32.6–34.7)
	Less than HS or HS only	33.6% (32.6–34.7)
Income Level	Less than \$40,000	49.7% (48.7–50.8)
	\$40,000-79,999	32.0% (31.0-33.1)
	\$80,000 or more	18.3% (17.5–19.0)
Main Activity	Employed	59.2% (58.1-60.2)
	Student	6.8% (6.1–7.5)
	Caregiving or Housework	8.4% (7.8–9.1)
	Retired or LTI	20.6% (20.0-21.2)
	Other	5.0% (4.4–5.6)
Mental Health	Good to Excellent	93.8% (93.2–94.4)
	Fair or Poor	6.2% (5.6–6.8)
Provinces	Atlantic Provinces	6.5% (6.4–6.6)
(Grouped)	Quebec	22.9% (22.7–23.2)
	Ontario	39.4% (39.1–39.7)
	Manitoba	3.4% (3.3–3.4)
	Saskatchewan	3.0% (2.9–3.0)
	Alberta	11.5% (11.3–11.6)
	British Columbia	13.3% (13.1–13.5)
	Territorial Capital Cities	0.05% (0.049–0.051)
Survey wave	1	32.9% (32.6-33.2)
	2	33.5% (33.2–33.8)
	3	33.7% (33.4–34.0)

1 Table 1: Weighted table of respondent characteristics (n = 27,808,08).

Percentage totals for ages and provinces do not add up to 100% exactly due to bootstrapping and
 rounding. HS = high school, LTI = long-term illness.



Page	29	of 28	
ruge	~ ~	0120	

1	Table 2: Variables associated with intent to try or increase cannabis use post-legalization (n =
2	27,808,081).

Variable	Levels	Unadjusted OR	Adjusted OR	Adjusted risk increase
		(95% CI)	(95% CI)	percent (95%CI)
Gender	Female	Ref.	Ref.	Ref.
	Male	1.3* (1.15–1.45)	1.1 (1.0–1.3)	N/a
Age	65 or older	Ref.	Ref.	Ref.
(years)	45-64	1.7* (1.4–2.1)	1.3 (1.0–1.6)	N/a
	35–44	2.8* (2.3-3.3)	1.8* (1.3–2.4)	6.8% (3.5–10.1)
	25–34	4.2* (3.5-5.1)	2.6* (1.9–3.4)	12.6% (8.8–16.4)
	15–24	5.3* (4.2–6.8)	3.8* (2.6–5.6)	20.1% (13.9–26.2)
Cannabis	No	Ref.	Ref.	Ref.
use in past	Yes	4.3* (3.7–5.0)	3.3* (2.8–3.9)	20.4% (17.1-23.6)
3 months				
Education	≥ Bachelor's	Ref.	Ref.	Ref.
Level	College or diploma	0.8* (0.7–0.9)	0.9 (0.7–1.0)	N/a
	≤HS	0.9 (0.8–1.1)	0.9 (0.8–1.1)	N/a
Income	< \$40,000	Ref.	Ref.	Ref.
Level	\$40-79,999	1.0 (0.8–1.1)	1.2* (1.0–1.4)	2.5% (0.3-4.7)
	≥ \$80,000	1.2* (1.1–1.4)	1.5* (1.3–1.9)	6.1% (3.2–9.0)
Main	Employed	Ref.	Ref.	Ref.
Activity	Student	1.4* (1.1–1.9)	0.9 (0.6–1.3)	N/a
	Caregiving or	0.8 (0.7–1.0)	1.0 (0.8–1.3)	N/a
	housework			
	Retired or LTI	0.4* (0.4–0.5)	0.9 (0.7–1.1)	N/a
	Other	1.1 (0.8–1.4)	0.8 (0.6–1.1)	N/a
Mental	Good to excellent	Ref.	Ref.	Ref.
Health	Poor or fair	2.6* (2.1-3.2)	2.0* (1.6-2.6)	11.5% (6.7–16.2)

* = Wald test for predictors being significant in model at p < 0.05.

5 Adjusted model included province/territory and survey wave.

N/a = an adjusted risk difference was not calculated for adjusted odd ratios that were not significant.